Gallium-68 RM2

Drug Profile

Gallium-68 RM2

Alternative Names: 68Ga-Bombesin; [(68)Ga]-labelled bombesin; [68GA]DOTA-4-AMINO-1-CARBOXYMETHYLPIPERIDINE-D-PHE-GLN-TRP-ALA-VAL-GLY-HIS-STA-LEU-NH2; [68Ga]RM2; BAY 867548; Bombesin (68Ga) labelled; Gallium-68-bombesin

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer National Cancer Institute (USA); Piramal Imaging
  • Class Imaging agents; Neuropeptides; Oligopeptides; Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 10 Apr 2017 Stanford University plans a phase II trial for Prostate cancer (Diagnosis) in USA (NCT03113617)
  • 01 Dec 2016 Piramal Imaging terminates a phase I/II trial in Prostate cancer (Diagnosis) in Austria, Finland due to a business decision (NCT02483884) (EudraCT2014-003027-21)
  • 01 Nov 2015 Phase-II/III clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT02624518)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top